22 April 2020 | News
The group is in the process of seeking approvals from ICMR and other authorities in order to start off clinical trials in India
A novel treatment invented by a team of scientists from European Medical Association, together with New Delhi based Redcliffe Lifesciences and Mumbai based Sapio Analytics, is proven to cure COVID-19 with higher effectiveness than conventional plasma treatment.
"We have innovated an accessible treatment of COVID-19, using the widely accepted concept of plasma treatment, and combining it with adjuvant negative ion therapy using a proprietary ionizer device. The treatment has already been applied in China and Germany (3000+ patients), with successful results, proving to be about 10 times more effective than conventional plasma therapy, with recovery rate of severe and acute patients being less than 48 hours”, informed the innovators of the treatment
The group is in the process of seeking approvals from ICMR and other authorities in order to start off clinical trials in India.
Dr. Ahmad Abdulaziz AlJaziri from UAE is the lead inventor, with Prof.em.Dr Amina Ather along with Dr.Nayak S.V under the umbrella of EMA as lead research and clinical leader. Redcliffe Lifesciences headed by Dheeraj Jain, Ashish Dubey and Rakesh Maurya is the exclusive commercial and clinical partner, while Sapio Analytics headed by Ashwin Srivastava and Hardik Somani is the government advisory, compliance, and planning partner.
Dr Jaziri has previously invented a number of medical devices, including and not limited to, Dr.AlJaziri Mosulator for removing abdominal tumors in a none invasive way, and Clip Applicator patented in Germany in 1990 Prof. Ather has been contributing on non-invasive non drug therapy as an emeritus professor with Peoples republic of china since 2013 .
“The treatment and its methodology are driven by data-based results of the said treatment of COVID-19 in UAE, China and Germany and combining the same with data-driven output models of plasma treatment and negative ion therapy, used outside of COVID-19. The methodology is designed and optimized in a manner that it can be administered on a range of patients with varying viral loads, using donors with varying levels of antibodies. This ability to create such a range makes it much more accessible than regular plasma treatment and helps usher India into an era of available COVID-19 treatment. The treatment is also combined with immune modulators of Phyto extracts and anti-influenza drugs”, adds the team about the methodology used in the treatment.
Recent reports say that Indian Council of Medical Research (ICMR) has received approvals for clinical trials of plasma treatment in India by the central drug regulator. A list of institutes have received approval for the same.
Sapio Umbrella, a brand entity of Sapio Analytics is already engaging with various state governments on a pro- bono basis to assist them with data backed decision support system, for combatting the pandemic.
Redcliffe is operating COVID-19 testing labs with partnership with DST’s BSIP and involved in whole genome sequencing of COVID-19 strain apart from distribution of the RT PCR kits.